Loading
GRB2 (Growth factor receptor-bound protein 2) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Myeloproliferative neoplasms and Chronic myeloid leukaemia.
Non-enzymatic adapter protein that plays a pivotal role in precisely regulated signalling cascades from cell surface receptors to cellular responses, including signalling transduction and gene expression. Thus, participates in many biological processes including regulation of innate and adaptive immunity, autophagy, DNA repair or necroptosis. Controls signalling complexes at the T-cell antigen receptor to facilitate the activation, differentiation, and function of T-cells.
Open Targets scores its association with cancer at 0.69 (direct and indirect evidence; datatypes literature 0.97, affected pathway 0.88, genetic association 0.00, clinical 0.18).
In plain words · GRB2 (Growth factor receptor-bound protein 2) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Myeloproliferative neoplasms and Chronic myeloid leukaemia.
GRB2 (Growth factor receptor-bound protein 2) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Myeloproliferative neoplasms and Chronic myeloid leukaemia.
Non-enzymatic adapter protein that plays a pivotal role in precisely regulated signalling cascades from cell surface receptors to cellular responses, including signalling transduction and gene expression.
No product in this corpus aims at GRB2 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Broadly expressed or essential: HPA finds the RNA at low tissue specificity; a medicine acting on the wild-type protein would expose normal tissue too. HPA GRB2: RNA low tissue specificity; high antibody staining in 5 normal tissues; highest cancer staining lymphoma (6 of 12 high). Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Leukaemia, Myeloid neoplasms); Open Targets associates it with 1 specific cancer type at or above 0.5 (chronic myeloid leukemia). (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas GRB2 tissue; Open Targets ENSG00000177885 associations
First described 1992. Earliest sequence paper UniProt cites for the protein: Lowenstein E.J. et al, Cell, 1992, "The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling". Source.
Sources: HGNC HGNC:4566 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P62993 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000177885 (association with cancer (MONDO_0004992) 0.69; per-cancer scores at or above 0.5: chronic myelogenous leukaemia, BCR-ABL1 positive 0.55, myeloproliferative neoplasm 0.59, leukaemia 0.59 (GraphQL API, CC0))
Non-enzymatic adapter protein that plays a pivotal role in precisely regulated signalling cascades from cell surface receptors to cellular responses, including signalling transduction and gene expression. Thus, participates in many biological processes including regulation of innate and adaptive immunity, autophagy, DNA repair or necroptosis. Controls signalling complexes at the T-cell antigen receptor to facilitate the activation, differentiation, and function of T-cells. Mechanistically, engagement of the TCR leads to phosphorylation of the adapter protein LAT, which serves as docking site for GRB2. In turn, GRB2 establishes a a connection with SOS1 that acts as a guanine nucleotide exchange factor and serves as a critical regulator of KRAS/RAF1 leading to MAPKs translocation to the nucleus and activation. Functions also a role in B-cell activation by amplifying Ca(2+) mobilisation and activation of the ERK MAP kinase pathway upon recruitment to the phosphorylated B-cell antigen receptor (BCR). Location: Nucleus; Cytoplasm; Endosome; Golgi apparatus (UniProt). Locus 17q25.1 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
Medium: Adipose tissue, Bone marrow, Breast, Caudate, Cerebral cortex, Colon, Duodenum, Endometrium.
Medium only: breast cancer, cervical cancer, colorectal cancer, endometrial cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"GRB2" OR ABSTRACT:"GRB2" OR TITLE:"growth factor receptor bound protein 2" OR ABSTRACT:"growth factor receptor bound protein 2" OR TITLE:"Growth factor receptor-bound protein 2" OR ABSTRACT:"Growth factor receptor-bound protein 2" OR TITLE:"NCKAP2" OR ABSTRACT:"NCKAP2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about GRB2, not a curated reading list.
Shares BCR::ABL1 (Philadelphia chromosome), Chronic myeloid leukaemia (KEGG map), Chronic myeloid leukaemia (CML), Myeloproliferative neoplasms (PV, ET, myelofibrosis).
Shares Chronic myeloid leukaemia (CML), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Open Targets Platform.
Shares Chronic myeloid leukaemia (CML), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Open Targets Platform.
Shares Chronic myeloid leukaemia (CML), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Open Targets Platform.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Open Targets Platform.
Shares Chronic myeloid leukaemia (CML), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Open Targets Platform.
Shares Chronic myeloid leukaemia (CML), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Open Targets Platform.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Open Targets Platform.